Cargando…
Superinduction of immunosuppressive glioblastoma extracellular vesicles by IFN-γ through PD-L1 and IDO1
BACKGROUND: Glioblastoma (GBM), the most common primary brain tumor, has a median survival of 15–16 months. Immunotherapy is promising but GBM-mediated immunosuppression remains a barrier. GBMs express the interferon-gamma (IFN-γ)-responsive immunosuppressive molecules programmed cell death ligand 1...
Autores principales: | Jung, Mi-Yeon, Aibaidula, Abudumijiti, Brown, Desmond A, Himes, Benjamin T, Cumba Garcia, Luz M, Parney, Ian F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389426/ https://www.ncbi.nlm.nih.gov/pubmed/35990703 http://dx.doi.org/10.1093/noajnl/vdac017 |
Ejemplares similares
-
Spectral flow cytometry identifies distinct nonneoplastic plasma extracellular vesicle phenotype in glioblastoma patients
por: Aibaidula, Abudumijiti (Zack), et al.
Publicado: (2023) -
Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications
por: Himes, Benjamin T., et al.
Publicado: (2021) -
Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma
por: Daniel, Paul, et al.
Publicado: (2022) -
Novel strategy for manufacturing autologous dendritic cell/allogeneic tumor lysate vaccines for glioblastoma
por: Parney, Ian F, et al.
Publicado: (2020) -
Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies
por: Adachi, Yusuke, et al.
Publicado: (2022)